1 Report Business Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Gene Modifying Immunotherapy for Blood Cancer Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
        1.2.2 CAR T-cell Therapy
        1.2.3 TCR T-cell Therapy
    1.3 Market by Application
        1.3.1 Global Gene Modifying Immunotherapy for Blood Cancer Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
        1.3.2 Acute Lymphocytic Leukemia
        1.3.3 Chronic Lymphocytic Leukemia
        1.3.4 B Cell Lymphoma
        1.3.5 Multiple Myeloma
        1.3.6 Other
    1.4 Study Objectives
    1.5 Years Considered
2 Global Growth Trends
    2.1 Global Gene Modifying Immunotherapy for Blood Cancer Market Perspective (2017-2028)
    2.2 Gene Modifying Immunotherapy for Blood Cancer Growth Trends by Region
        2.2.1 Gene Modifying Immunotherapy for Blood Cancer Market Size by Region: 2017 VS 2021 VS 2028
        2.2.2 Gene Modifying Immunotherapy for Blood Cancer Historic Market Size by Region (2017-2022)
        2.2.3 Gene Modifying Immunotherapy for Blood Cancer Forecasted Market Size by Region (2023-2028)
    2.3 Gene Modifying Immunotherapy for Blood Cancer Market Dynamics
        2.3.1 Gene Modifying Immunotherapy for Blood Cancer Industry Trends
        2.3.2 Gene Modifying Immunotherapy for Blood Cancer Market Drivers
        2.3.3 Gene Modifying Immunotherapy for Blood Cancer Market Challenges
        2.3.4 Gene Modifying Immunotherapy for Blood Cancer Market Restraints
3 Competition Landscape by Key Players
    3.1 Global Top Gene Modifying Immunotherapy for Blood Cancer Players by Revenue
        3.1.1 Global Top Gene Modifying Immunotherapy for Blood Cancer Players by Revenue (2017-2022)
        3.1.2 Global Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share by Players (2017-2022)
    3.2 Global Gene Modifying Immunotherapy for Blood Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Gene Modifying Immunotherapy for Blood Cancer Revenue
    3.4 Global Gene Modifying Immunotherapy for Blood Cancer Market Concentration Ratio
        3.4.1 Global Gene Modifying Immunotherapy for Blood Cancer Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Gene Modifying Immunotherapy for Blood Cancer Revenue in 2021
    3.5 Gene Modifying Immunotherapy for Blood Cancer Key Players Head office and Area Served
    3.6 Key Players Gene Modifying Immunotherapy for Blood Cancer Product Solution and Service
    3.7 Date of Enter into Gene Modifying Immunotherapy for Blood Cancer Market
    3.8 Mergers & Acquisitions, Expansion Plans
4 Gene Modifying Immunotherapy for Blood Cancer Breakdown Data by Type
    4.1 Global Gene Modifying Immunotherapy for Blood Cancer Historic Market Size by Type (2017-2022)
    4.2 Global Gene Modifying Immunotherapy for Blood Cancer Forecasted Market Size by Type (2023-2028)
5 Gene Modifying Immunotherapy for Blood Cancer Breakdown Data by Application
    5.1 Global Gene Modifying Immunotherapy for Blood Cancer Historic Market Size by Application (2017-2022)
    5.2 Global Gene Modifying Immunotherapy for Blood Cancer Forecasted Market Size by Application (2023-2028)
6 North America
    6.1 North America Gene Modifying Immunotherapy for Blood Cancer Market Size (2017-2028)
    6.2 North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Type
        6.2.1 North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2017-2022)
        6.2.2 North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2023-2028)
        6.2.3 North America Gene Modifying Immunotherapy for Blood Cancer Market Share by Type (2017-2028)
    6.3 North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Application
        6.3.1 North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2017-2022)
        6.3.2 North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2023-2028)
        6.3.3 North America Gene Modifying Immunotherapy for Blood Cancer Market Share by Application (2017-2028)
    6.4 North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Country
        6.4.1 North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2017-2022)
        6.4.2 North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2023-2028)
        6.4.3 U.S.
        6.4.4 Canada
7 Europe
    7.1 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size (2017-2028)
    7.2 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Type
        7.2.1 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2017-2022)
        7.2.2 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2023-2028)
        7.2.3 Europe Gene Modifying Immunotherapy for Blood Cancer Market Share by Type (2017-2028)
    7.3 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Application
        7.3.1 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2017-2022)
        7.3.2 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2023-2028)
        7.3.3 Europe Gene Modifying Immunotherapy for Blood Cancer Market Share by Application (2017-2028)
    7.4 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Country
        7.4.1 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2017-2022)
        7.4.2 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2023-2028)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic Countries
8 Asia-Pacific
    8.1 Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Market Size (2017-2028)
    8.2 Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Market Size by Type
        8.2.1 Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2017-2022)
        8.2.2 Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2023-2028)
        8.2.3 Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Market Share by Type (2017-2028)
    8.3 Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Market Size by Application
        8.3.1 Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2017-2022)
        8.3.2 Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2023-2028)
        8.3.3 Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Market Share by Application (2017-2028)
    8.4 Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Market Size by Region
        8.4.1 Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Market Size by Region (2017-2022)
        8.4.2 Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Market Size by Region (2023-2028)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia 
9 Latin America
    9.1 Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size (2017-2028)
    9.2 Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Type
        9.2.1 Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2017-2022)
        9.2.2 Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2023-2028)
        9.2.3 Latin America Gene Modifying Immunotherapy for Blood Cancer Market Share by Type (2017-2028)
    9.3 Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Application
        9.3.1 Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2017-2022)
        9.3.2 Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2023-2028)
        9.3.3 Latin America Gene Modifying Immunotherapy for Blood Cancer Market Share by Application (2017-2028)
    9.4 Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Country
        9.4.1 Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2017-2022)
        9.4.2 Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2023-2028)
        9.4.3 Mexico
        9.4.4 Brazil
10 Middle East & Africa
    10.1 Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size (2017-2028)
    10.2 Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size by Type
        10.2.1 Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2017-2022)
        10.2.2 Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2023-2028)
        10.2.3 Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Share by Type (2017-2028)
    10.3 Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size by Application
        10.3.1 Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2017-2022)
        10.3.2 Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2023-2028)
        10.3.3 Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Share by Application (2017-2028)
    10.4 Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size by Country
        10.4.1 Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2017-2022)
        10.4.2 Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2023-2028)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE
11 Key Players Profiles
    11.1 Novartis
        11.1.1 Novartis Company Details
        11.1.2 Novartis Business Overview
        11.1.3 Novartis Gene Modifying Immunotherapy for Blood Cancer Introduction
        11.1.4 Novartis Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2017-2022)
        11.1.5 Novartis Recent Developments
    11.2 Kite Pharma
        11.2.1 Kite Pharma Company Details
        11.2.2 Kite Pharma Business Overview
        11.2.3 Kite Pharma Gene Modifying Immunotherapy for Blood Cancer Introduction
        11.2.4 Kite Pharma Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2017-2022)
        11.2.5 Kite Pharma Recent Developments
    11.3 Juno Therapeutics
        11.3.1 Juno Therapeutics Company Details
        11.3.2 Juno Therapeutics Business Overview
        11.3.3 Juno Therapeutics Gene Modifying Immunotherapy for Blood Cancer Introduction
        11.3.4 Juno Therapeutics Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2017-2022)
        11.3.5 Juno Therapeutics Recent Developments
    11.4 Cellectis
        11.4.1 Cellectis Company Details
        11.4.2 Cellectis Business Overview
        11.4.3 Cellectis Gene Modifying Immunotherapy for Blood Cancer Introduction
        11.4.4 Cellectis Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2017-2022)
        11.4.5 Cellectis Recent Developments
    11.5 Ziopharm Oncology
        11.5.1 Ziopharm Oncology Company Details
        11.5.2 Ziopharm Oncology Business Overview
        11.5.3 Ziopharm Oncology Gene Modifying Immunotherapy for Blood Cancer Introduction
        11.5.4 Ziopharm Oncology Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2017-2022)
        11.5.5 Ziopharm Oncology Recent Developments
    11.6 Celyad
        11.6.1 Celyad Company Details
        11.6.2 Celyad Business Overview
        11.6.3 Celyad Gene Modifying Immunotherapy for Blood Cancer Introduction
        11.6.4 Celyad Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2017-2022)
        11.6.5 Celyad Recent Developments
    11.7 Bluebird Bio
        11.7.1 Bluebird Bio Company Details
        11.7.2 Bluebird Bio Business Overview
        11.7.3 Bluebird Bio Gene Modifying Immunotherapy for Blood Cancer Introduction
        11.7.4 Bluebird Bio Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2017-2022)
        11.7.5 Bluebird Bio Recent Developments
    11.8 Bellicum Pharmaceuticals
        11.8.1 Bellicum Pharmaceuticals Company Details
        11.8.2 Bellicum Pharmaceuticals Business Overview
        11.8.3 Bellicum Pharmaceuticals Gene Modifying Immunotherapy for Blood Cancer Introduction
        11.8.4 Bellicum Pharmaceuticals Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2017-2022)
        11.8.5 Bellicum Pharmaceuticals Recent Developments
    11.9 Mustang Bio
        11.9.1 Mustang Bio Company Details
        11.9.2 Mustang Bio Business Overview
        11.9.3 Mustang Bio Gene Modifying Immunotherapy for Blood Cancer Introduction
        11.9.4 Mustang Bio Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2017-2022)
        11.9.5 Mustang Bio Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Author Details
    13.3 Disclaimer
                  
              

                

                 
List of Tables
    Table 1. Global Gene Modifying Immunotherapy for Blood Cancer Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
    Table 2. Key Players of CAR T-cell Therapy
    Table 3. Key Players of TCR T-cell Therapy
    Table 4. Global Gene Modifying Immunotherapy for Blood Cancer Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
    Table 5. Global Gene Modifying Immunotherapy for Blood Cancer Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
    Table 6. Global Gene Modifying Immunotherapy for Blood Cancer Market Size by Region (2017-2022) & (US$ Million)
    Table 7. Global Gene Modifying Immunotherapy for Blood Cancer Market Share by Region (2017-2022)
    Table 8. Global Gene Modifying Immunotherapy for Blood Cancer Forecasted Market Size by Region (2023-2028) & (US$ Million)
    Table 9. Global Gene Modifying Immunotherapy for Blood Cancer Market Share by Region (2023-2028)
    Table 10. Gene Modifying Immunotherapy for Blood Cancer Market Trends
    Table 11. Gene Modifying Immunotherapy for Blood Cancer Market Drivers
    Table 12. Gene Modifying Immunotherapy for Blood Cancer Market Challenges
    Table 13. Gene Modifying Immunotherapy for Blood Cancer Market Restraints
    Table 14. Global Gene Modifying Immunotherapy for Blood Cancer Revenue by Players (2017-2022) & (US$ Million)
    Table 15. Global Gene Modifying Immunotherapy for Blood Cancer Revenue Share by Players (2017-2022)
    Table 16. Global Top Gene Modifying Immunotherapy for Blood Cancer by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gene Modifying Immunotherapy for Blood Cancer as of 2021)
    Table 17. Ranking of Global Top Gene Modifying Immunotherapy for Blood Cancer Companies by Revenue (US$ Million) in 2021
    Table 18. Global 5 Largest Players Market Share by Gene Modifying Immunotherapy for Blood Cancer Revenue (CR5 and HHI) & (2017-2022)
    Table 19. Key Players Headquarters and Area Served
    Table 20. Key Players Gene Modifying Immunotherapy for Blood Cancer Product Solution and Service
    Table 21. Date of Enter into Gene Modifying Immunotherapy for Blood Cancer Market
    Table 22. Mergers & Acquisitions, Expansion Plans
    Table 23. Global Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2017-2022) & (US$ Million)
    Table 24. Global Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share by Type (2017-2022)
    Table 25. Global Gene Modifying Immunotherapy for Blood Cancer Forecasted Market Size by Type (2023-2028) & (US$ Million)
    Table 26. Global Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share by Type (2023-2028)
    Table 27. Global Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2017-2022) & (US$ Million)
    Table 28. Global Gene Modifying Immunotherapy for Blood Cancer Revenue Share by Application (2017-2022)
    Table 29. Global Gene Modifying Immunotherapy for Blood Cancer Forecasted Market Size by Application (2023-2028) & (US$ Million)
    Table 30. Global Gene Modifying Immunotherapy for Blood Cancer Revenue Share by Application (2023-2028)
    Table 31. North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2017-2022) & (US$ Million)
    Table 32. North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2023-2028) & (US$ Million)
    Table 33. North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2017-2022) & (US$ Million)
    Table 34. North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2023-2028) & (US$ Million)
    Table 35. North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2017-2022) & (US$ Million)
    Table 36. North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2023-2028) & (US$ Million)
    Table 37. Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2017-2022) & (US$ Million)
    Table 38. Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2023-2028) & (US$ Million)
    Table 39. Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2017-2022) & (US$ Million)
    Table 40. Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2023-2028) & (US$ Million)
    Table 41. Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2017-2022) & (US$ Million)
    Table 42. Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2023-2028) & (US$ Million)
    Table 43. Asia Pacific Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2017-2022) & (US$ Million)
    Table 44. Asia Pacific Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2023-2028) & (US$ Million)
    Table 45. Asia Pacific Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2017-2022) & (US$ Million)
    Table 46. Asia Pacific Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2023-2028) & (US$ Million)
    Table 47. Asia Pacific Gene Modifying Immunotherapy for Blood Cancer Market Size by Region (2017-2022) & (US$ Million)
    Table 48. Asia Pacific Gene Modifying Immunotherapy for Blood Cancer Market Size by Region (2023-2028) & (US$ Million)
    Table 49. Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2017-2022) & (US$ Million)
    Table 50. Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2023-2028) & (US$ Million)
    Table 51. Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2017-2022) & (US$ Million)
    Table 52. Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2023-2028) & (US$ Million)
    Table 53. Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2017-2022) & (US$ Million)
    Table 54. Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2023-2028) & (US$ Million)
    Table 55. Middle East and Africa Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2017-2022) & (US$ Million)
    Table 56. Middle East and Africa Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2023-2028) & (US$ Million)
    Table 57. Middle East and Africa Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2017-2022) & (US$ Million)
    Table 58. Middle East and Africa Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2023-2028) & (US$ Million)
    Table 59. Middle East and Africa Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2017-2022) & (US$ Million)
    Table 60. Middle East and Africa Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2023-2028) & (US$ Million)
    Table 61. Novartis Company Details
    Table 62. Novartis Business Overview
    Table 63. Novartis Gene Modifying Immunotherapy for Blood Cancer Product
    Table 64. Novartis Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2017-2022) & (US$ Million)
    Table 65. Novartis Recent Developments
    Table 66. Kite Pharma Company Details
    Table 67. Kite Pharma Business Overview
    Table 68. Kite Pharma Gene Modifying Immunotherapy for Blood Cancer Product
    Table 69. Kite Pharma Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2017-2022) & (US$ Million)
    Table 70. Kite Pharma Recent Developments
    Table 71. Juno Therapeutics Company Details
    Table 72. Juno Therapeutics Business Overview
    Table 73. Juno Therapeutics Gene Modifying Immunotherapy for Blood Cancer Product
    Table 74. Juno Therapeutics Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2017-2022) & (US$ Million)
    Table 75. Juno Therapeutics Recent Developments
    Table 76. Cellectis Company Details
    Table 77. Cellectis Business Overview
    Table 78. Cellectis Gene Modifying Immunotherapy for Blood Cancer Product
    Table 79. Cellectis Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2017-2022) & (US$ Million)
    Table 80. Cellectis Recent Developments
    Table 81. Ziopharm Oncology Company Details
    Table 82. Ziopharm Oncology Business Overview
    Table 83. Ziopharm Oncology Gene Modifying Immunotherapy for Blood Cancer Product
    Table 84. Ziopharm Oncology Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2017-2022) & (US$ Million)
    Table 85. Ziopharm Oncology Recent Developments
    Table 86. Celyad Company Details
    Table 87. Celyad Business Overview
    Table 88. Celyad Gene Modifying Immunotherapy for Blood Cancer Product
    Table 89. Celyad Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2017-2022) & (US$ Million)
    Table 90. Celyad Recent Developments
    Table 91. Bluebird Bio Company Details
    Table 92. Bluebird Bio Business Overview
    Table 93. Bluebird Bio Gene Modifying Immunotherapy for Blood Cancer Product
    Table 94. Bluebird Bio Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2017-2022) & (US$ Million)
    Table 95. Bluebird Bio Recent Developments
    Table 96. Bellicum Pharmaceuticals Company Details
    Table 97. Bellicum Pharmaceuticals Business Overview
    Table 98. Bellicum Pharmaceuticals Gene Modifying Immunotherapy for Blood Cancer Product
    Table 99. Bellicum Pharmaceuticals Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2017-2022) & (US$ Million)
    Table 100. Bellicum Pharmaceuticals Recent Developments
    Table 101. Mustang Bio Company Details
    Table 102. Mustang Bio Business Overview
    Table 103. Mustang Bio Gene Modifying Immunotherapy for Blood Cancer Product
    Table 104. Mustang Bio Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2017-2022) & (US$ Million)
    Table 105. Mustang Bio Recent Developments
    Table 106. Research Programs/Design for This Report
    Table 107. Key Data Information from Secondary Sources
    Table 108. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Gene Modifying Immunotherapy for Blood Cancer Market Share by Type: 2021 VS 2028
    Figure 2. CAR T-cell Therapy Features
    Figure 3. TCR T-cell Therapy Features
    Figure 4. Global Gene Modifying Immunotherapy for Blood Cancer Market Share by Application: 2021 VS 2028
    Figure 5. Acute Lymphocytic Leukemia Case Studies
    Figure 6. Chronic Lymphocytic Leukemia Case Studies
    Figure 7. B Cell Lymphoma Case Studies
    Figure 8. Multiple Myeloma Case Studies
    Figure 9. Other Case Studies
    Figure 10. Gene Modifying Immunotherapy for Blood Cancer Report Years Considered
    Figure 11. Global Gene Modifying Immunotherapy for Blood Cancer Market Size (US$ Million), Year-over-Year: 2017-2028
    Figure 12. Global Gene Modifying Immunotherapy for Blood Cancer Market Size, (US$ Million), 2017 VS 2021 VS 2028
    Figure 13. Global Gene Modifying Immunotherapy for Blood Cancer Market Share by Region: 2021 VS 2028
    Figure 14. Global Gene Modifying Immunotherapy for Blood Cancer Market Share by Players in 2021
    Figure 15. Global Top Gene Modifying Immunotherapy for Blood Cancer Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gene Modifying Immunotherapy for Blood Cancer as of 2021)
    Figure 16. The Top 10 and 5 Players Market Share by Gene Modifying Immunotherapy for Blood Cancer Revenue in 2021
    Figure 17. North America Gene Modifying Immunotherapy for Blood Cancer Market Size YoY (2017-2028) & (US$ Million)
    Figure 18. North America Gene Modifying Immunotherapy for Blood Cancer Market Size Market Share by Type (2017-2028)
    Figure 19. North America Gene Modifying Immunotherapy for Blood Cancer Market Size Market Share by Application (2017-2028)
    Figure 20. North America Gene Modifying Immunotherapy for Blood Cancer Market Size Share by Country (2017-2028)
    Figure 21. United States Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 22. Canada Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 23. Europe Gene Modifying Immunotherapy for Blood Cancer Market Size YoY (2017-2028) & (US$ Million)
    Figure 24. Europe Gene Modifying Immunotherapy for Blood Cancer Market Size Market Share by Type (2017-2028)
    Figure 25. Europe Gene Modifying Immunotherapy for Blood Cancer Market Size Market Share by Application (2017-2028)
    Figure 26. Europe Gene Modifying Immunotherapy for Blood Cancer Market Size Share by Country (2017-2028)
    Figure 27. Germany Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 28. France Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 29. U.K. Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 30. Italy Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 31. Russia Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 32. Nordic Countries Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 33. Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Market Size YoY (2017-2028) & (US$ Million)
    Figure 34. Asia Pacific Gene Modifying Immunotherapy for Blood Cancer Market Size Market Share by Type (2017-2028)
    Figure 35. Asia Pacific Gene Modifying Immunotherapy for Blood Cancer Market Size Market Share by Application (2017-2028)
    Figure 36. Asia Pacific Gene Modifying Immunotherapy for Blood Cancer Market Size Share by Region (2017-2028)
    Figure 37. China Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 38. Japan Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 39. South Korea Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 40. Southeast Asia Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 41. India Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 42. Australia Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
    Figure 43. Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size YoY (2017-2028) & (US$ Million)
    Figure 44. Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size Market Share by Type (2017-2028)
    Figure 45. Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size Market Share by Application (2017-2028)
    Figure 46. Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size Share by Country (2017-2028)
    Figure 47. Mexico Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 48. Brazil Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 49. Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size YoY (2017-2028) & (US$ Million)
    Figure 50. Middle East and Africa Gene Modifying Immunotherapy for Blood Cancer Market Size Market Share by Type (2017-2028)
    Figure 51. Middle East and Africa Gene Modifying Immunotherapy for Blood Cancer Market Size Market Share by Application (2017-2028)
    Figure 52. Middle East and Africa Gene Modifying Immunotherapy for Blood Cancer Market Size Share by Country (2017-2028)
    Figure 53. Turkey Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 54. Saudi Arabia Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 55. UAE Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 56. Novartis Revenue Growth Rate in Gene Modifying Immunotherapy for Blood Cancer Business (2017-2022)
    Figure 57. Kite Pharma Revenue Growth Rate in Gene Modifying Immunotherapy for Blood Cancer Business (2017-2022)
    Figure 58. Juno Therapeutics Revenue Growth Rate in Gene Modifying Immunotherapy for Blood Cancer Business (2017-2022)
    Figure 59. Cellectis Revenue Growth Rate in Gene Modifying Immunotherapy for Blood Cancer Business (2017-2022)
    Figure 60. Ziopharm Oncology Revenue Growth Rate in Gene Modifying Immunotherapy for Blood Cancer Business (2017-2022)
    Figure 61. Celyad Revenue Growth Rate in Gene Modifying Immunotherapy for Blood Cancer Business (2017-2022)
    Figure 62. Bluebird Bio Revenue Growth Rate in Gene Modifying Immunotherapy for Blood Cancer Business (2017-2022)
    Figure 63. Bellicum Pharmaceuticals Revenue Growth Rate in Gene Modifying Immunotherapy for Blood Cancer Business (2017-2022)
    Figure 64. Mustang Bio Revenue Growth Rate in Gene Modifying Immunotherapy for Blood Cancer Business (2017-2022)
    Figure 65. Bottom-up and Top-down Approaches for This Report
    Figure 66. Data Triangulation
    Figure 67. Key Executives Interviewed